Breaking Through the Barriers of Tumor Therapy: Absin Helps Photodynamic Gel Bombs Achieve Precise and Efficient Treatment

In the field of tumor therapy, how to enable drugs to reach the lesion more accurately and deeply has always been a difficult problem for researchers to overcome. Recently, a groundbreaking study titled Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies published in the journal Signal Transduction and Targeted Therapy showed that a new type of photodynamic gel bomb (DCM@OPR) significantly improved the therapeutic effect on breast cancer through an "explosive penetration" mechanism. Among them, Absin's Ready-to-Use immunohistochemical secondary antibody kit (for both mouse and rabbit) (abs996) played a key role, providing core support for the accurate verification of the experimental results.

 
Core Breakthrough: The "Dual-Driven" Penetration Mechanism of Photodynamic Gel-Bombs
 
Traditional nanomedicines rely on passive diffusion to penetrate tumors, resulting in low efficiency. In contrast, photodynamic gel-bombs achieve active and highly efficient tumor penetration through photodynamically triggered explosive energy and receptor-mediated transcytosis:
 
➷ Under laser irradiation, the gel-bombs release a large amount of reactive oxygen species (ROS), fragment into nano-pieces, and penetrate the intercellular spaces of tumor cells by virtue of explosive energy;
➷ The nano-pieces penetrate deep into tumor tissues through transcytosis, and at the same time destroy lysosomal membranes to avoid degradation, greatly increasing the accumulation of drugs.
 
This "active-driven" mechanism increases the accumulation of therapeutic components in the deep tumor by several times compared with traditional methods, and has shown excellent tumor-inhibiting effects in 4T1 breast cancer models, MDA-MB-231 xenograft models, and patient-derived xenograft (PDX) models.
 
Absin abs996: The "Unsung Hero" for Accurate Verification of Therapeutic Effects

In this study, Absin's secondary antibody kit (Cat. No.: abs996) provided key support for immunohistochemistry (IHC) experiments and became a core tool for verifying therapeutic effects:
 
1. Product function: amplify signals and accurately locate target proteins
 
The abs996 secondary antibody kit specifically binds to primary antibodies (such as Ki67 and CD34 antibodies), efficiently amplifying the signal of antigen-antibody complexes, enabling clear detection of the expression levels of proliferation marker (Ki67) and vascular marker (CD34) in tumor tissues.
 
➷ Ki67: reflects the proliferative activity of tumor cells; the lower the expression, the stronger the therapeutic inhibitory effect;
➷ CD34: marks tumor neovascularization; the reduced expression indicates that angiogenesis is effectively inhibited.
 
The research team processed tumor tissue sections with the abs996 kit and combined with IHC staining to achieve:

➷ Intuitive comparison: the proportion of Ki67 and CD34 positive cells in the DCM@OPR + laser group was significantly lower than that in other groups (as shown in Figure 1), directly proving that the treatment plan can effectively inhibit tumor proliferation and angiogenesis;
➷ Data quantification: analysis of staining intensity by Image-Pro Plus software showed that the expression of Ki67 in the DCM@OPR + laser group was 62% lower than that in the free DOX group, and CD34 was 58% lower, providing an objective basis for efficacy evaluation.

From mechanism exploration to efficacy verification, Absin's abs996 secondary antibody kit, with its high sensitivity and specificity, has helped the research team clearly demonstrate the therapeutic advantages of photodynamic gel-bombs. This study not only provides a new strategy for the treatment of solid tumors, but also shows the key supporting role of high-quality experimental tools in scientific research breakthroughs.
 
In the future, Absin will continue to provide more comprehensive reagent solutions for fields such as oncology and nanomedicine, helping more innovative therapies move from the laboratory to the clinic and bringing new hope to cancer patients.
 
References:
Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies.
Signal Transduct Target Ther. 2025 Mar 19;10:94. doi: 10.1038/s41392-025-02186-y
 
Related Products
 

Catalog No.	Name	Specification
abs996	Ready to use immunohistochemical secondary antibody kit (anti rabbit&mouse)	5mL
abs957	Ready to use high-efficiency immunohistochemical secondary antibody kit	5mL
abs998	Ready to use immunohistochemical secondary antibody kit (anti rabbit)	5mL
abs997	Ready to use immunohistochemical secondary antibody kit (anti mouse)	5mL